Trial of Cre8 polymer-free stent (CID) shows promising results for patients with Coronary Artery Lesions

Researchers have found that the Cre8 polymer-free amphilimus-eluting stents, from Carbostent and Implantable Devices(CID), in de novo coronary artery lesions showed a significantly lower in-stent late loss at six months compared to paclitaxel-eluting stents with permanent polymers. NEXT is a prospective, randomized trial comparing Cre8 polymer-free amphilimus-eluting stent to a paclitaxel-eluting stent. A total of 323 patients were enrolled, with 162 randomized to Cre8 stents and 161 to paclitaxel-eluting stents. In-stent late loss (the difference between the diameter of a stented segment post-procedure compared with the follow-up angiogram)was significantly lower with amphilimus-eluting stents (0.14�0.36 mm vs. 0.34�0.40 mm, P<0.0001 for non-inferiority, p><0.0001 for superiority). clinical endpoints (cardiac death, myocardial infarction, target lesion revascularization or stent thrombosis) up to 12 months did not differ significantly. further studies are warranted to prove that this polymer-free stent can improve the risk-benefit balance of coronary drug-eluting stents, according to lead researcher didier carri�, professor of medicine, cardiology at the university of paul sabatier in toulouse, france. results of the next trial were presented today at the 23rd annual transcatheter cardiovascular therapeutics (tct) scientific symposium.>